Kiniksa Pharmaceuticals International Plc (KNSA)
77.09
-0.82
(-1.05%)
USD |
NASDAQ |
Sep 08, 16:00
80.00
+2.91
(+3.77%)
After-Hours: 20:00
Kiniksa Pharmaceuticals International Net Income (Quarterly) : 25.43M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 25.43M |
| March 31, 2026 | 22.59M |
| December 31, 2025 | 14.20M |
| September 30, 2025 | 18.44M |
| June 30, 2025 | 17.83M |
| March 31, 2025 | 8.539M |
| December 31, 2024 | -8.888M |
| September 30, 2024 | -12.69M |
| June 30, 2024 | -3.908M |
| March 31, 2024 | -17.70M |
| December 31, 2023 | 25.24M |
| September 30, 2023 | -13.86M |
| June 30, 2023 | 14.97M |
| March 31, 2023 | -12.27M |
| December 31, 2022 | 4.461M |
| September 30, 2022 | 224.09M |
| June 30, 2022 | -19.98M |
| March 31, 2022 | -25.21M |
| December 31, 2021 | -36.33M |
| Date | Value |
|---|---|
| September 30, 2021 | -30.54M |
| June 30, 2021 | -41.56M |
| March 31, 2021 | -49.48M |
| December 31, 2020 | -53.66M |
| September 30, 2020 | -43.84M |
| June 30, 2020 | -37.47M |
| March 31, 2020 | -26.42M |
| December 31, 2019 | -31.80M |
| September 30, 2019 | -27.06M |
| June 30, 2019 | -37.19M |
| March 31, 2019 | -65.82M |
| December 31, 2018 | -42.58M |
| September 30, 2018 | -24.41M |
| June 30, 2018 | -20.26M |
| March 31, 2018 | -15.98M |
| December 31, 2017 | -32.70M |
| September 30, 2017 | -16.03M |
| June 30, 2017 | -11.20M |
| March 31, 2017 | -4.941M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Autolus Therapeutics Plc | -39.18M |
| Barinthus Biotherapeutics Plc | -10.62M |
| Scancell Holdings Plc | -- |
| OptiBiotix Health Plc | -- |
| Immunocore Holdings Plc | -0.8095M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 243.60M |
| Total Expenses (Quarterly) | 218.17M |
| EPS Diluted (Quarterly) | 0.305 |
| Enterprise Value | 5.494B |
| Gross Profit Margin (Quarterly) | 54.10% |
| Profit Margin (Quarterly) | 10.44% |
| Earnings Yield | 1.28% |
| Operating Earnings Yield | 1.59% |
| Normalized Earnings Yield | 1.276 |